GlassScriptPhysician profile
Samantha Anderson
NPI 1568577245
$2,525.32
in general payments reported to CMS, 2019-2025
35 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $252 · 2021: $498 · 2022: $530 · 2023: $458 · 2024: $187 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.83 | 2019-2023 | Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $193.19 | 2023-2025 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $163.16 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.26 | 2019-2024 | |
| Evofem Biosciences, INC. | $142.73 | 2021-2023 | Phexxi |
| Astellas Pharma US INC | $108.35 | 2023-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $96.57 | 2021-2022 | |
| Lupin INC. | $84.36 | 2019-2021 | |
| Channel Medsystems, INC. | $65.65 | 2023 | |
| Dysis Medical, INC. | $60.48 | 2022 | |
| Avion Pharmaceuticals | $57.42 | 2020-2023 | Balcoltra |
| Therapeuticsmd, INC. | $57.28 | 2021-2022 | |
| Organon LLC | $54.85 | 2022-2025 | Nexplanon |
| Optumhealth Care Solutions, LLC | $53.10 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Pfizer INC. | $46.69 | 2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $44.42 | 2023-2024 | Slynd |
| Allergan, INC. | $39.89 | 2019-2020 | |
| Agile Therapeutics, INC. | $34.20 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.11 | 2022-2024 | Gardasil 9, Gardasil |
| Vertical Pharmaceuticals, LLC | $30.82 | 2019 | |
| Meditrina | $30.42 | 2022 | |
| Aspira Women'S Health INC | $29.97 | 2020-2021 | |
| Mylan Pharmaceuticals INC. | $29.83 | 2021 | |
| Biogen, INC. | $26.71 | 2024 | Zurzuvae |
| Medicem INC. | $26.53 | 2020 | |
| Covidien LP | $23.65 | 2019 | |
| Glaxosmithkline, LLC. | $20.17 | 2020 | |
| Shield Therapeutics INC | $19.95 | 2022 | |
| Roche Diagnostics Corporation | $18.04 | 2019 | |
| Mission Pharmacal Company | $16.77 | 2021 | |
| Hologic Sales and Service, LLC | $16.47 | 2021 | |
| Millicent US INC | $16.30 | 2020 | |
| Seqirus USA INC | $15.87 | 2022 | |
| Coopersurgical, INC. | $11.28 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.